Effects of irbesartan on the expression of matrix metalloproteinase-2/tissue inhibitor of metalloproteinase-2 in streptozotocin-induced diabetic rat kidney.
Liu
Bi-cheng
BC
Institute of Nephrology, Zhongda Hospital, Southeast University School of Medicine, Nanjing 210009, China. kidney@jlonline.com
Xu
Yan
Y
Ma
Kun-ling
KL
Huang
Hai-quan
HQ
Yin
Lian-fang
LF
Liu
Dian-ge
DG
D047228:Angiotensin II Type 1 Receptor Blockers / Q000494:pharmacology*; D000818:Animals; D001713:Biphenyl Compounds / Q000494:pharmacology*; D003404:Creatinine / Q000378:metabolism; D003921:Diabetes Mellitus, Experimental / Q000378:metabolism* / Q000473:pathology; D006984:Hypertrophy; D007150:Immunohistochemistry; D000077405:Irbesartan; D007668:Kidney / Q000378:metabolism* / Q000473:pathology; D008297:Male; D020778:Matrix Metalloproteinase 2 / Q000032:analysis* / Q000235:genetics; D051381:Rats; D017207:Rats, Sprague-Dawley; D013311:Streptozocin; D013777:Tetrazoles / Q000494:pharmacology*; D019716:Tissue Inhibitor of Metalloproteinase-2 / Q000032:analysis* / Q000235:genetics
D047228:Angiotensin II Type 1 Receptor Blockers; D001713:Biphenyl Compounds; D013777:Tetrazoles; D019716:Tissue Inhibitor of Metalloproteinase-2; D013311:Streptozocin; D003404:Creatinine; D020778:Matrix Metalloproteinase 2; D000077405:Irbesartan